Keywords: Zymeworks Theravance deal, ZYME acquisition, TBPH buyout, biotech M&A 2026, Theravance clinical setback, biopharma consolidation

Key Highlights

  • Zymeworks Inc. (NASDAQ:ZYME) completed its Acquisition of Theravance Biopharma, Inc. (NASDAQ:TBPH) on September 23, 2026, roughly three months after the deal was first announced.
  • The transaction was valued at approximately USD 929 million, with Zymeworks paying USD 17.00 per share in cash.
  • The sale followed clinical setbacks at Theravance that had pressured the company to pursue strategic alternatives.
  • Zymeworks management is scheduled to discuss integration details on September 28, 2026.

Deal Closes After Three Month Process

Zymeworks completed its acquisition of Theravance Biopharma on September 23, 2026, after first agreeing to the deal in late June 2026. The all cash transaction was valued at approximately USD 929 million, with Zymeworks paying USD 17.00 per share for Theravance shares, a price that reflected Theravance's diminished standalone prospects following setbacks in its clinical pipeline.

Why Theravance Sold

Theravance had faced clinical setbacks in the period leading up to the deal, pressuring the company's board to explore a sale rather than continue funding development independently. The acquisition gives Zymeworks additional clinical and commercial Assets while providing Theravance shareholders a defined cash outcome rather than continued exposure to pipeline risk.

Integration Details Ahead

Zymeworks management is scheduled to discuss integration plans on September 28, 2026, when the company is expected to outline how Theravance's assets and personnel will be folded into its existing operations and pipeline priorities. Investors will be watching for details on cost synergies and how the combined pipeline will be prioritized going forward.

Where Things Stand

With the acquisition now closed, Zymeworks has added Theravance Biopharma's assets to its portfolio for approximately USD 929 million, and the upcoming September 28 integration briefing should clarify how the combined company plans to prioritize its expanded pipeline going forward.